Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Risk Stratification in HF with mid-range LVEF: the role of Cardiopulmonary Exercise Testing
Session:
Painel 1 -Insuficiencia cardiaca 3
Speaker:
Bruno M. Rocha
Congress:
CPC 2020
Topic:
D. Heart Failure
Theme:
10. Chronic Heart Failure
Subtheme:
10.2 Chronic Heart Failure – Epidemiology, Prognosis, Outcome
Session Type:
Posters
FP Number:
---
Authors:
Bruno M. Rocha; Gonçalo Lopes Da Cunha; Pedro M Lopes; Pedro Freitas; Francisco Fernandes Gama; Catarina Brízido; Christopher Strong; Maria João Andrade; António Tralhão; António Ventosa; Carlos Aguiar; Anai Durazzo; Miguel Mendes
Abstract
<p><strong>Background: </strong>Cardiopulmonary exercise testing (CPET) is recommended in the evaluation of selected patients with Heart Failure (HF). Notwithstanding, its prognostic significance has mainly been ascertained in those with left ventricular ejection fraction (LVEF) <40% (i.e., HFrEF). The main goal of our study was to assess the role of CPET in risk stratification of HF with mid-range (40-49%) LVEF (i.e., HFmrEF) compared to HFrEF.</p> <p><strong>Methods: </strong>We conducted a single-center retrospective study of consecutive patients with HF and LVEF <50% who underwent CPET from 2003-2018. The primary composite endpoint of death, heart transplant or HF hospitalization was assessed.</p> <p><strong>Results: </strong>Overall, 404 HF patients (mean age 57 ± 11 years, 78.2% male, 55.4% ischemic HF) were included, of whom 321 (79.5%) had HFrEF and 83 (20.5%) HFmrEF. Compared to the former, those with HFmrEF had a significantly higher mean peak oxygen uptake (pVO<sub>2</sub>) (20.2 ± 6.1 vs 16.1 ± 5.0mL/Kg/min; p<0.001), lower median minute ventilation/carbon dioxide production (VE/VCO<sub>2</sub>) [35.0 (IQR: 29.1-41.2) vs 39.0 (IQR: 32.0-47.0); p=0.002) and fewer patients with exercise oscillatory ventilation (EOV) (22.0 vs 46.3%; p<0.001). Over a median follow-up of 28.7 (IQR: 13.0-92.3) months, 117 (28.9%) patients died, 53 (13.1%) underwent heart transplantation, and 134 (33.2%) had at least one HF hospitalization. In both HFmrEF and HFrEF, pVO<sub>2</sub> <12mL/Kg/min, VE/VCO2 >35 and EOV identified patients at higher risk for events (all p<0.05). In Cox regression multivariate analysis, pVO<sub>2</sub> was predictive of the primary endpoint in both HFmrEF and HFrEF (HR per +1mL/Kg/min: 0.81; CI: 0.72-0.92; p=0.001; and HR per +1mL/Kg/min: 0.92; CI: 0.87-0.97; p=0.004), as was EOV (HR: 4.79; CI: 1.41-16.39; p=0.012; and HR: 2.15; CI: 1.51-3.07; p<0.001). VE/VCO<sub>2</sub>, on the other hand, was predictive of events in HFrEF but not in HFmrEF (HR per unit: 1.03; CI: 1.02-1.05; p<0.001; and HR per unit: 0.99; CI: 0.95-1.03; p=0.512, respectively). ROC curve analysis demonstrated that a pVO2 >16.7 and >15.8 mL/Kg/min more accurately identified patients at lower risk for the primary endpoint (NPV: 91.2 and 60.5% for HFmrEF and HFrEF, respectively; both p<0.001).</p> <p><strong>Conclusions: </strong>CPET is a useful tool in HFmrEF. Both pVO<sub>2</sub> and EOV independently predicted the primary endpoint in HFmrEF and HFrEF, contrasting with VE/VCO<sub>2</sub>, which remained predictive only in latter group. Our findings strengthen the prognostic role of CPET in HF with either reduced or mid-range LVEF.</p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site